Karyopharm Therapeutics Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing therapies that target nuclear transport pathways to treat cancer and other serious diseases. The company develops small-molecule Selective Inhibitors of Nuclear Export (SINE), which inhibit exportin 1 (XPO1), a key nuclear export protein, through a differentiated mechanism of action.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Karyopharm is engaged in supporting independent research aligned with its areas of research interest, which include Investigational Sponsored Research (ISR), Investigator Initiated Research (IIR), Investigator Sponsored Trials (IST), Investigator Initiated Trials (IIT), and Outcomes Research (OR). The company's Global Medical Research (GMR) program focuses on areas such as Selinexor in Multiple Myeloma, Endometrial Cancer, Myelofibrosis, and Eltanexor, as well as Selinexor in underrepresented patient populations and pediatric patients with malignancy. The company provides support in the form of drug supply and funding for independent research proposals submitted through its PORE Request Management System. In FY2025, the company spent US$125.6 million on R&D, which, as a percentage of revenue, stood at 86% and grew 12.2% YoY. Karyopharm holds 53 patents in the US, has 13 pending patent applications in the US, two pending international applications filed under the Patent Cooperation Treaty (PCT), 189 granted patents, and 79 pending patent applications in foreign jurisdictions. Selinexor (KPT-330) has two US patents covering selinexor’s composition of matter; Eltanexor (KPT-8602) consists of five issued US patents, two pending non-provisional US patent applications, 29 issued foreign patents, and 16 pending foreign patent applications; PAK4/NAMPT Inhibitors such as KPT-9274 consist of five patent families with eight issued US patents, 26 issued foreign patents, one pending US non-provisional patent application, and two pending foreign patent applications. In addition to the patent portfolios covering key products and product candidates, the company's patent portfolio also includes 16 patents in the US and 53 granted foreign patents and pending patent applications in the US. Some of the pipeline products in phase III include Selinexor for the treatment of Myelofibrosis (JAKi-naive); Endometrial cancer (maintenance; p53 wild-type); Multiple myeloma (2L+; post anti–CD38); Endometrial cancer (maintenance); and DLBCL (R/R). Pipeline products in phase II include Selinexor to treat Myelofibrosis (JAKi-naive) and Multiple myeloma (relapsed/refractory); and Eltanexor for the treatment of Myelodysplastic neoplasms (relapsed/refractory).